Misty Dawn Shields, Assistant Professor at Indiana University School of Medicine, shared a post by IU Simon Comprehensive Cancer Center on X, adding:
“Thank you IU Simon Comprehensive Cancer Center for highlighting The Shields Lab research on a novel biomarker ISL1 and new neuroendocrine subtype for SCLC that predicts durable responses to lurbinectedin. More research on ISL1 coming soon! So proud of our team at IU School of Medicine in collaboration with Moffitt Cancer Center for their diligent work and dedication, leading to these meaningful discoveries!”
Quotting IU Simon Comprehensive Cancer Center‘s post:
“Gain valuable insights from a new article published in Molecular Cancer Therapeutics by the cancer center’s Misty D. Shields, our trainee Katherine G. Minton, Tianhao Zhou, Olivia C. Terry, Paresh Kumar, and colleagues. ”
Title: ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin
Authors: Misty D. Shields, Katherine G. Minton, Hilal Ozakinci, Tianhao Zhou, Olivia C. Terry, Paresh Kumar, Reem Akel, Luc Girard, John D. Minna, Theresa A. Boyle, John M. Koomen, Michael Shafique
Read the article: here.
Other articles about Misty Dawn Shields on OncoDaily.
